Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
birinapant + irinotecan
- Development stage
- Phase 2
- Lead developer
- Medivir
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Birinapant + irinotecan** is an investigational pharmaceutical drug combination used in oncology research. Birinapant is a small molecule SMAC mimetic that antagonizes inhibitor of apoptosis proteins (IAPs) including cIAP1 and XIAP, promoting apoptosis in cancer cells. Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding, causing DNA damage and cell death in rapidly dividing cells. Combination therapy is being studied for synergistic antitumor effects, where birinapant sensitizes cancer cells—particularly colorectal and other solid tumors—to chemotherapy-induced cell death by restoring apoptotic signaling and overcoming chemoresistance, potentially enhancing the cytotoxicity of irinotecan.
- Other names
- birinapant and irinotecanTL32711 + irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)XIAPBIRC2 (Cellular inhibitor of apoptosis protein 1)BIRC3 (Baculoviral IAP repeat-containing protein 3)
Beyond the preview
Go deeper on birinapant + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on birinapant + irinotecan.